Page 86 - JCTR-11-3

Journal of Clinical and

Translational Research

ORIGINAL ARTICLE
Clinical characteristics and outcomes of

hospitalized coronavirus disease 2019 patients
treated with remdesivir in Saudi Arabia: A 1-year

retrospective study

Basem M. Alraddadi * , Abdullah Alraddadi 1 , Lama Hefni 1 ,
1,2
Yazeed Waleed Alfadl 1 , Wafaa Adel Toonsi 1 , and Mohammad Al Hroub 1
1 King Faisal Specialist Hospital and Research Center Jeddah, Jeddah, Saudi Arabia King Faisal
Specialist Hospital and Research Center, Jeddah, Saudi Arabia
2 Department of Medical, Alfaisal University, Riyadh, Saudi Arabia

Abstract
Background: The recent pandemic caused by coronavirus disease 2019 (COVID-19)
has resulted in increased deaths globally, and effective treatment is crucial as a form
of disease management. Aims: This study was aimed to describe the epidemiological
characteristics and outcomes of hospitalized COVID-19 patients who have been
*Corresponding author: administered with remdesivir (RDV) at King Faisal Specialized Hospital in Saudi Arabia.
Basem M Alraddadi Methods: Hospitalized COVID-19 adult patients who received RDV therapy (from
(balraddadi@kfshrc.edu.sa)
January to December 2021) were included in this retrospective case series. Patients’
Citation: Alraddadi BM, demographics, medical history, presenting symptoms, and laboratory results were
Alraddadi A, Hefni L, Alfadl YW,
Toonsi WA, Al Hroub M. Clinical collected. Statistical analyses were performed using the Statistical Packages for
characteristics and outcomes the Social Sciences and data were presented based on their statistical variables.
of hospitalized coronavirus Results: A total of 210 patients (56.1% females, 43.9% males) with a mean ± standard
disease 2019 patients treated
with remdesivir in Saudi Arabia: A deviation (SD) age of 57.43 ± 18.4 years were included in our analysis. Pneumonia
1-year retrospective study. J Clin was manifested in 52.4% of patients. The most common associated comorbidities
Transl Res. 2025;11(3):80-87. were hypertension (54.76%) and diabetes (44.76%). From 180 participants that
doi: 10.36922/jctr.24.00027 were vaccinated, 73 and 90 patients received two or three COVID-19 vaccine doses,
Received: June 13, 2024 respectively. The most frequent presenting symptoms were fever (80.1%) and cough
Revised: August 28, 2024 (62.6%). About 48.1% and 10.48% of the cohort received RDV with dexamethasone
or tocilizumab, respectively. Overall, 45.71% of the patients needed oxygen therapy
Accepted: March 26, 2025 during hospitalization, and 21 patients with pneumonia required mechanical
Published Online: May 21, 2025 ventilation for a mean ± SD of 15.15 ± 16.46 days with the mean ± SD length of the
Copyright: © 2025 Author(s). hospital stay which was 14.9 ± 46.29 days. Moreover, 41 patients were admitted to
This is an Open-Access article the intensive care unit for a mean ± SD stay of 10.5 ± 11.05 days, and 26 patients had
distributed under the terms of the died. Conclusion: Despite previous vaccination, a significant portion of hospitalized
Creative Commons AttributionNon-
Commercial 4.0 International (CC COVID-19 patients in our cohort required oxygen therapy and experienced longer
BY-NC 4.0), which permits all periods of hospital stay, highlighting the seriousness of COVID-19 infection for
non-commercial use, distribution, some patients regardless of vaccination status. Relevance for patients: This study
and reproduction in any medium,
provided the original work is highlights RDV’s role in reducing oxygen need and hospitalization duration, aiding
properly cited. better outcomes for COVID-19 patients.
Publisher’s Note: AccScience
Publishing remains neutral with Keywords: Coronavirus disease-2019; Remdesivir; Saudi Arabia; Vaccination; Intensive
regard to jurisdictional claims in
published maps and institutional care unit
affiliations.

Volume 11 Issue 3 (2025) 80 doi: 10.36922/jctr.24.00027